AbbVie (ABBV) Maintains Immunology Dominance as Analysts Downplay Competitive Threat From J&J’s Tremfya to Skyrizi Market Share

Core Insights - AbbVie Inc. is highlighted as a strong investment opportunity for the next decade, with recent price target increases from Morgan Stanley and HSBC indicating positive market sentiment [1][2]. Financial Performance - In Q3 2025, AbbVie reported total net revenues of approximately $15.8 billion, marking a 9.10% year-over-year increase, driven by growth in immunology and neuroscience treatments [3]. - The company earned $1.86 per share, surpassing estimates by $0.08 [3]. - The immunology segment generated $7.9 billion in revenue, reflecting an 11.2% increase [3]. Product Performance - Skyrizi sales surged by 46% to $4.7 billion, while Rinvoq sales increased by 34.1% to around $2.2 billion, contributing significantly to revenue growth [4]. - The decline of Humira was noted, with sales dropping 55.7% to $993 million due to the impact of biosimilars [4]. - The oncology sector remained stable, generating $1.7 billion in revenue, with newer drugs like Venclexta offsetting price negotiation impacts on Imbruvica [4]. Market Position - Analysts have downplayed competitive threats from Johnson & Johnson's Tremfya, asserting it is unlikely to significantly impact Skyrizi's market dominance [2].